Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses

Clinical Cancer Research

Volumn 23, Issue 9, 2017, Pages 2223-2231

  Vanderstichele, Adriaan ^a,b   Busschaert, Pieter ^a,b   Smeets, Dominiek ^c,d   Landolfo, Chiara ^a   Van Nieuwenhuysen, Els ^a,b   Leunen, Karin ^a,b   Neven, Patrick ^a,b   Amant, Frédéric ^a,b,e   Mahner, Sven ^f,g   Braicu, Elena Ioana ^h   Zeilinger, Robert ⁱ   Coosemans, An ^a,b   Timmerman, Dirk ^a   Lambrechts, Diether ^c,d   Vergote, Ignace ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CELL FREE DNA; DNA; UNCLASSIFIED DRUG; CELL FREE NUCLEIC ACID; TUMOR MARKER;

ADNEXA DISEASE; ADNEXAL MASS; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; COPY NUMBER VARIATION; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; DNA EXTRACTION; FEMALE; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; OVARY CANCER; OVARY TUMOR; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RISK OF MALIGNANCY INDEX; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; WHOLE GENOME SEQUENCING; BLOOD; COMPLICATION; GENETICS; MIDDLE AGED; PATHOLOGY;

ADNEXAL DISEASES; ADULT; AGED; BIOMARKERS, TUMOR; CA-125 ANTIGEN; CELL-FREE NUCLEIC ACIDS; CHROMOSOMAL INSTABILITY; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 85018416387     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1078     Document Type: Article

References (37)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014;384:1376-88.
3. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295-303.
4. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet 2015;387:945-56.
5. Menon U, Griffin M, Gentry-Maharaj A. Ovarian cancer screening-current status, future directions. Gynecol Oncol 2014;132:490-5.
6. Bianchi DW, Chudova D, Sehnert AJ, Bhatt S, Murray K, Prosen TL, et al. Noninvasive prenatal testing and incidental detection of occult maternal malignancies. JAMA 2015;314:162-9.
7. Amant F, Verheecke M, Wlodarska I, Dehaspe L, Brady P, Brison N, et al. Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing. JAMA Oncol 2015;1:814-9.
8. Pikor L, Thu K, Vucic E, Lam W. The detection and implication of genome instability in cancer. Cancer Metastasis Rev 2013;32: 341-52.
9. Vandenberghe P, Wlodarska I, Tousseyn T, Dehaspe L, Dierickx D, Verheecke M, et al. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: A technical proof-of-principle study. Lancet Haematol 2015;2:e55-65.
10. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of adnexal masses. Obstetrics and gynecology 2007;110:201-14.
11. Kaijser J, Sayasneh A, Van Hoorde K, Ghaem-Maghami S, Bourne T, Timmerman D, et al. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: A systematic review and meta-analysis. Hum Reprod Update 2014;20:449-62.
12. Timmerman D, Van Calster B, Testa A, Savelli L, Fischerova D, Froyman W, et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol 2016;214:424-37.
13. Rauh-Hain JA, Krivak TC, Del Carmen MG, Olawaiye AB. Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol 2011;4:15-21.
14. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-9.
15. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-60.
16. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009;25: 2078-9.
17. Scheinin I, Sie D, Bengtsson H, van deWielMA, Olshen AB, van Thuijl HF, et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res 2014;24:2022-32.
18. Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A 2010;107:16910-5.
19. Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 2013;5:30.
20. Sing T, SanderO, Beerenwinkel N, Lengauer T. ROCR: Visualizing classifier performance in R. Bioinformatics 2005;21:3940-1.
21. Kuhn M.Building predictive models in R using the caret package. Journal of Statistical Software 2008;28:1-26.
22. Despierre E, Moisse M, Yesilyurt B, Sehouli J, Braicu I, Mahner S, et al. Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. Gynecol Oncol 2014;135:415-22.
23. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
24. Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, et al. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Clin Cancer Res 2014; 20:6618-30.
25. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125. Am J Obstet Gynecol 2008; 199:215-23.
26. Meys EM, Kaijser J, Kruitwagen RF, Slangen BF, Van Calster B, Aertgeerts B, et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. Eur J Cancer 2016;58:17-29.
27. Gusnanto A, Tcherveniakov P, Shuweihdi F, Samman M, Rabbitts P, Wood HM. Stratifying tumour subtypes based on copy number alteration profiles using next-generation sequence data. Bioinformatics 2015;31:2713-20.
28. Kaijser J, Bourne T, Valentin L, Sayasneh A, Van Holsbeke C, Vergote I, et al. Improving strategies for diagnosing ovarian cancer: A summary of the International Ovarian Tumor Analysis (IOTA) studies. Ultrasound Obstet Gynecol 2013;41:9-20.
29. Pereira E, Camacho-Vanegas O, Anand S, Sebra R, Catalina Camacho S, Garnar-Wortzel L, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers. PLoS One 2015;10:e0145754.
30. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013;45:1127-33.
31. Chien J, Sicotte H, Fan JB, Humphray S, Cunningham JM, Kalli KR, et al. TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. Nucleic Acids Res 2015;43:6945-58.
32. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012;4:162ra154.
33. Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der BurgM, et al. Epithelial ovarian cancer: rationale for changing the one-fitsall standard treatment regimen to subtype-specific treatment. Int J Gynecol Cancer 2014;24:468-77.
34. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108-12.
35. Mohan S,Heitzer E, Ulz P, Lafer I, Lax S, Auer M, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet 2014;10:e1004271.
36. Xia S, Huang CC, Le M, Dittmar R, Du M, Yuan T, et al. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls. Lung Cancer 2015;90:78-84.
37. Schütz E, Akbari MR, Beck J, Urnovitz H, Zhang WW, Bornemann-Kolatzki K, et al. Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. Clin Chem 2015;61:239-48.